PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 21, 2026The Lancet8 citations

Cumulative incidence of advanced breast cancer in women aged 40–49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis

View Full Paper
NHNarumi Harada-ShojiASAkihiko SuzukiTITakanori Ishida

Key Points

  • This analysis evaluates the long-term effects of adjunctive ultrasonography on advanced breast cancer incidence in asymptomatic women aged 40-49.
  • Randomised controlled trial design with 72,661 women
  • Participants assigned to ultrasonography with mammography or mammography alone
  • Cumulative incidence assessed up to October 2024 based on TNM classification
  • Median follow-up of approximately 11.4 years.
  • 26% of detected cancers in the ultrasonography group were advanced versus 33% in the control group
  • Hazard ratio for advanced cancer incidence was 0.83, p=0.026
  • Divergence in cancer incidence between groups appeared around year four and stabilized thereafter.

Abstract

The J-START randomised controlled trial found that adjunctive ultrasonography was associated with significantly higher rates of breast cancer detection than mammography alone. This report aims to evaluate the long-term effect of adjunctive ultrasonography screening on the cumulative incidence of advanced breast cancer as a prespecified secondary outcome of J-START. We enrolled asymptomatic women in 42 study sites in 23 of 47 prefectures in Japan. Eligible women were aged 40–49 years without a history of breast cancer, including in-situ cancer, or other cancers in the previous 5 years, and who had a life expectancy of more than 5 years. Participants were assigned in a 1:1 ratio to undergo ultrasonography with mammography (intervention group) or mammography alone (control group) twice during a 2-year screening period by individual or cluster randomisation. Participants attended an initial screening appointment and were then asked to return for a second screening after 2 years. This prespecified secondary analysis assessed the cumulative incidence of stage 2 or higher breast cancers based on the TNM classification up to data cutoff on Oct 4, 2024. Between Aug 2, 2007, and March 31, 2011, 72 661 asymptomatic women aged 40–49 years were randomly assigned (36 723 in the intervention group and 35 938 in the control group). Median follow-up for this secondary analysis was 11·4 years (range 0·0–16·1; IQR 9·3–12·9) in the intervention group and 11·3 years (0·0–16·1; 8·9–12·9) in the control group. Of 894 breast cancers detected in the intervention group, 234 (26%) were advanced cancers, compared with 277 (33%) of 843 detected breast cancers in the control group (hazard ratio 0·83 95·6% CI 0·70–0·98; p=0·026). Kaplan–Meier curves suggested a violation of the proportional hazards assumption, with a significant difference in advanced cancer incidence only between 48 months and 96 months. Divergence between groups emerged around year four, widened until year eight, and remained stable thereafter. Adjunctive ultrasonography reduced the cumulative incidence of advanced breast cancer in women aged 40–49 years. These findings highlight the potential value of integrating adjunctive ultrasonography into screening programmes for women with dense breast tissue, particularly in Asian populations, and could inform future breast cancer screening guidelines. The Ministry of Health, Labor, and Welfare (Japan) and Japan Agency for Medical Research and Development.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Harada-Shoji et al. (2026) studied this question.

synapsesocial.com/papers/69990de85b97ab4c14ac27eahttps://doi.org/10.1016/s0140-6736(25)02319-0
Ask AI
Helpful
Bookmark
Share
View Full Paper